MFT
MRTX

Moisand Fitzgerald Tamayo’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 913
2022
Q2 		$0 Sell
2
-2
-50% -$127 ﹤0.01% 700
2022
Q1 		$0 Buy
+4
New +$409 ﹤0.01% 686

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Moisand Fitzgerald Tamayo's MRTX Position: Q3 2022 in Review

Moisand Fitzgerald Tamayo sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 2 shares.

Moisand Fitzgerald Tamayo first reported a position in MRTX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

  • Moisand Fitzgerald Tamayo reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 2 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Moisand Fitzgerald Tamayo first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Moisand Fitzgerald Tamayo's Mirati Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2022, filed 26 Oct 2022.